文献速递瓣膜外科

新型生物瓣膜主动脉瓣置换五年真实世界多中心注册研究结果

Five-Year Results of Aortic Valve Replacement With a Novel Bioprosthesis: Real-World Data From a Large Multicenter Registry.
PubMed 文献 · Ann Thorac Surg · 2025-03-24

该研究为前瞻性、多中心、真实世界注册研究,纳入7个欧洲心脏外科中心498例使用新型无戊二醛生物瓣行外科主动脉瓣置换的患者,平均年龄60.1岁,EuroSCORE II均值3.9%,女性占27.9%,中位随访4.8年。结果显示5年结构性瓣膜退化1、2、3期免除率分别为95.7%、98.6%、99.3%,全因生存率93.2%,心血管死亡免除率97.2%,瓣膜功能稳定。

要点

  • 新型无戊二醛生物瓣5年结构性瓣膜退化1期免除率95.7%,耐久性良好
  • 5年全因生存率93.2%,心血管死亡免除率97.2%,安全性可接受
  • 平均主动脉瓣压差出院时中位11.0 mmHg,5年时12.0 mmHg,血流动力学稳定

核心结论

  • 新型主动脉生物瓣在真实世界中5年耐久性和安全性结果良好,血流动力学表现稳定。

研究设计与样本

  • 前瞻性、多中心、真实世界注册研究,纳入7个欧洲心脏外科中心所有使用该新型生物瓣行外科主动脉瓣置换的患者,共498例。

主要发现

  • 5年结构性瓣膜退化1、2、3期免除率分别为95.7%、98.6%、99.3%。
  • 估计5年总生存率93.2%,心血管死亡免除率97.2%。
  • 5年感染性心内膜炎、卒中、再干预的免除概率分别为98.6%、98.1%、98.2%。
  • 中重度瓣周漏少见,5年免除概率97.3%。
  • 平均主动脉瓣压差出院时中位11.0 mmHg,5年时12.0 mmHg。

临床怎么用

  • 该新型生物瓣5年数据支持其在外科主动脉瓣置换中的应用,尤其适用于关注瓣膜耐久性和血流动力学稳定的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical performance and safety of a glutaraldehyde-free bioprosthetic valve using a novel tissue treatment in a large real-world patient population have not previously been reported. METHODS: This is a prospective, multicenter, real-world registry of all patients undergoing surgical aortic valve replacement with a novel bioprosthesis at 7 European cardiac surgery centers. The primary end point was the 5-year freedom from structural valve deterioration per Valve Academic Research Consortium 3 criteria. Secondary end points included hemodynamic performance of the bioprosthesis and freedom from all-cause and cardiovascular mortality, prosthetic endocarditis, stroke, and reintervention at 5 years. RESULTS: A total of 498 patients were included in the analysis; the mean age was 60.1 years, with a mean EuroSCORE II of 3.9% and 27.9% being female. The median follow-up was 4.8 years. Five-year freedom from structural valve deterioration stages 1, 2, and 3 was 95.7%, 98.6%, and 99.3%, respectively. The estimated 5-year overall survival was 93.2%; freedom from cardiovascular mortality was 97.2%. Event-free probabilities at 5 years for endocarditis, stroke, and reintervention were 98.6%, 98.1%, and 98.2%, respectively. Moderate-severe paravalvular leakage was infrequent (97.3% event-free probability at 5 years), and mean aortic valve pressure gradient was stable compared with discharge (median, 11.0 mm Hg at discharge vs 12.0 mm Hg at 5 years). CONCLUSIONS: These real-world clinical data of a novel aortic bioprosthesis demonstrated good 5-year results for both durability and safety outcomes as well as stable hemodynamic valve performance.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Onorati F, Geisler D, Theron A, et al. Five-Year Results of Aortic Valve Replacement With a Novel Bioprosthesis: Real-World Data From a Large Multicenter Registry. Ann Thorac Surg. 2025. PMID: 40139625. doi:10.1016/j.athoracsur.2025.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。